RNA疫苗-话题@MedSci

#RNA疫苗#

127篇内容 | 3071人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947434, encodeId=3f1a194e4342a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, objectType=article, longId=219261, objectId=3c982192618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c982192618a, replyNumber=0, likeNumber=70, createdTime=2022-02-01, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c982192618a, moduleTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c982192618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947431, encodeId=59b1194e431ce, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Front Immunol：免疫抑制疗法不同程度地调节类风湿关节炎患者对COVID-19 mRNA疫苗的体液和T细胞特异性反应。, objectType=article, longId=218420, objectId=747a2184204c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=747a2184204c, replyNumber=0, likeNumber=64, createdTime=2022-05-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=747a2184204c, moduleTitle=Front Immunol：免疫抑制疗法不同程度地调节类风湿关节炎患者对COVID-19 mRNA疫苗的体液和T细胞特异性反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=747a2184204c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947416, encodeId=4aba194e41633, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=以色列78%新冠疫苗接种率，日新增高达6000例；mRNA疫苗真的有效吗？, objectType=article, longId=216379, objectId=12042163e9c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12042163e9c0, replyNumber=0, likeNumber=55, createdTime=2022-05-27, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12042163e9c0, moduleTitle=以色列78%新冠疫苗接种率，日新增高达6000例；mRNA疫苗真的有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12042163e9c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947395, encodeId=6e58194e395d6, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=世卫：南非将建立mRNA疫苗技术转移中心, objectType=article, longId=213109, objectId=e1d6213109be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d6213109be, replyNumber=0, likeNumber=115, createdTime=2022-04-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d6213109be, moduleTitle=世卫：南非将建立mRNA疫苗技术转移中心, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d6213109be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947380, encodeId=2ce7194e38003, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Moderna疫苗有效性降至90%, objectType=article, longId=209971, objectId=47632099e1e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47632099e1e1, replyNumber=0, likeNumber=53, createdTime=2021-05-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47632099e1e1, moduleTitle=Moderna疫苗有效性降至90%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47632099e1e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, objectType=article, longId=216995, objectId=8c02216995b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c02216995b9, replyNumber=0, likeNumber=65, createdTime=2022-02-07, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c02216995b9, moduleTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c02216995b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947447, encodeId=c181194e44709, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=bioRxiv：mRNA疫苗2.0！魏文胜团队开发环状RNA疫苗，对德尔塔和奥密克戎有效, objectType=article, longId=294422, objectId=c3fb29442244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fb29442244, replyNumber=0, likeNumber=63, createdTime=2022-12-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fb29442244, moduleTitle=bioRxiv：mRNA疫苗2.0！魏文胜团队开发环状RNA疫苗，对德尔塔和奥密克戎有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fb29442244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947406, encodeId=cdfb194e4061f, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Circulation：COVID-19 mRNA疫苗接种后心肌炎的特征, objectType=article, longId=214931, objectId=1238214931fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1238214931fc, replyNumber=0, likeNumber=67, createdTime=2022-03-14, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1238214931fc, moduleTitle=Circulation：COVID-19 mRNA疫苗接种后心肌炎的特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1238214931fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947442, encodeId=dca8194e442c8, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JAMA：新冠肺炎感染康复人群接种RNA疫苗可获得更好的保护力, objectType=article, longId=220926, objectId=994e22092641, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=994e22092641, replyNumber=0, likeNumber=77, createdTime=2022-05-17, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=994e22092641, moduleTitle=JAMA：新冠肺炎感染康复人群接种RNA疫苗可获得更好的保护力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=994e22092641)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947405, encodeId=0200194e40546, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Nat Med：异源ChAdOx1 nCoV-19/mRNA疫苗的免疫原性和反应原性 , objectType=article, longId=214903, objectId=0209214903db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0209214903db, replyNumber=0, likeNumber=56, createdTime=2021-08-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0209214903db, moduleTitle=Nat Med：异源ChAdOx1 nCoV-19/mRNA疫苗的免疫原性和反应原性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0209214903db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947409, encodeId=9a13194e40920, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JASN：血液透析和肾移植患者接种SARS-CoV-2 mRNA疫苗效果如何？, objectType=article, longId=215429, objectId=7b39215429ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b39215429ae, replyNumber=0, likeNumber=91, createdTime=2021-09-24, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b39215429ae, moduleTitle=JASN：血液透析和肾移植患者接种SARS-CoV-2 mRNA疫苗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b39215429ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947446, encodeId=33e7194e4465d, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Kidney Int: 评价第3剂mRNA疫苗在接受维持性血液透析患者中的合理性、安全性和疗效, objectType=article, longId=221623, objectId=e4c3221623e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c3221623e8, replyNumber=0, likeNumber=100, createdTime=2022-07-08, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c3221623e8, moduleTitle=Kidney Int: 评价第3剂mRNA疫苗在接受维持性血液透析患者中的合理性、安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c3221623e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947385, encodeId=e0c1194e385be, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Nat Med：新冠mRNA疫苗在我国的I期临床结果发布, objectType=article, longId=210762, objectId=889a210e62d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889a210e62d3, replyNumber=0, likeNumber=49, createdTime=2022-04-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889a210e62d3, moduleTitle=Nat Med：新冠mRNA疫苗在我国的I期临床结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889a210e62d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947396, encodeId=81e9194e39697, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle= CDC小组称mRNA疫苗与罕见的心脏炎症病例之间可能存在联系, objectType=article, longId=213175, objectId=bf872131e56a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf872131e56a, replyNumber=0, likeNumber=72, createdTime=2021-08-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf872131e56a, moduleTitle= CDC小组称mRNA疫苗与罕见的心脏炎症病例之间可能存在联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf872131e56a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947392, encodeId=7906194e39299, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=Blood：CLL患者接种新冠BNT162b2 mRNA疫苗后的抗体反应, objectType=article, longId=212723, objectId=640a212e23de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=640a212e23de, replyNumber=0, likeNumber=87, createdTime=2021-09-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=640a212e23de, moduleTitle=Blood：CLL患者接种新冠BNT162b2 mRNA疫苗后的抗体反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=640a212e23de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947417, encodeId=ed3b194e417d0, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=沃森生物新冠mRNA疫苗获墨西哥、印度尼西亚批准Ⅲ期临床, objectType=article, longId=216611, objectId=0b56216611d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b56216611d3, replyNumber=0, likeNumber=73, createdTime=2022-04-13, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b56216611d3, moduleTitle=沃森生物新冠mRNA疫苗获墨西哥、印度尼西亚批准Ⅲ期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b56216611d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947387, encodeId=429b194e38733, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=JAMA：COVID-19 mRNA疫苗在孕妇和哺乳期妇女中的免疫原性, objectType=article, longId=211300, objectId=3b922113006f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b922113006f, replyNumber=0, likeNumber=73, createdTime=2022-01-19, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b922113006f, moduleTitle=JAMA：COVID-19 mRNA疫苗在孕妇和哺乳期妇女中的免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b922113006f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947440, encodeId=b298194e440f8, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=新冠mRNA疫苗进入人体后，是如何发挥作用的？, objectType=article, longId=220431, objectId=929922043160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=929922043160, replyNumber=0, likeNumber=69, createdTime=2022-05-08, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=929922043160, moduleTitle=新冠mRNA疫苗进入人体后，是如何发挥作用的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=929922043160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947379, encodeId=b44b194e37933, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=mRNA疫苗，你只知道新冠？那你要来看看这个了, objectType=article, longId=209740, objectId=c65d209e402f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65d209e402f, replyNumber=0, likeNumber=56, createdTime=2022-03-07, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65d209e402f, moduleTitle=mRNA疫苗，你只知道新冠？那你要来看看这个了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c65d209e402f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, objectTitle=首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破, objectType=article, longId=209998, objectId=35c620999849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c620999849, replyNumber=0, likeNumber=56, createdTime=2021-10-09, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c620999849, moduleTitle=首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c620999849)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RNA疫苗

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展

2022-02-01

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Front Immunol：免疫抑制疗法不同程度地调节类风湿关节炎患者对COVID-19 mRNA疫苗的体液和T细胞特异性反应。

2022-05-25

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

以色列78%新冠疫苗接种率，日新增高达6000例；mRNA疫苗真的有效吗？

2022-05-27

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

世卫：南非将建立mRNA疫苗技术转移中心

2022-04-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Moderna疫苗有效性降至90%

2021-05-03

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖

2022-02-07

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

bioRxiv：mRNA疫苗2.0！魏文胜团队开发环状RNA疫苗，对德尔塔和奥密克戎有效

2022-12-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Circulation：COVID-19 mRNA疫苗接种后心肌炎的特征

2022-03-14

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JAMA：新冠肺炎感染康复人群接种RNA疫苗可获得更好的保护力

2022-05-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Nat Med：异源ChAdOx1 nCoV-19/mRNA疫苗的免疫原性和反应原性

2021-08-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JASN：血液透析和肾移植患者接种SARS-CoV-2 mRNA疫苗效果如何？

2021-09-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Kidney Int: 评价第3剂mRNA疫苗在接受维持性血液透析患者中的合理性、安全性和疗效

2022-07-08

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Nat Med：新冠mRNA疫苗在我国的I期临床结果发布

2022-04-03

智者为医08 (审核中...)

前往app查看评论内容

#RNA疫苗#

CDC小组称mRNA疫苗与罕见的心脏炎症病例之间可能存在联系

2021-08-21

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

Blood：CLL患者接种新冠BNT162b2 mRNA疫苗后的抗体反应

2021-09-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

沃森生物新冠mRNA疫苗获墨西哥、印度尼西亚批准Ⅲ期临床

2022-04-13

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

JAMA：COVID-19 mRNA疫苗在孕妇和哺乳期妇女中的免疫原性

2022-01-19

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

新冠mRNA疫苗进入人体后，是如何发挥作用的？

2022-05-08

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

mRNA疫苗，你只知道新冠？那你要来看看这个了

2022-03-07

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#RNA疫苗#

首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破

2021-10-09

科室
- - 订阅+
  - 更多科室
工具
服务